These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35716099)
1. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients. Gluck M; Hodak E; Davidovici B Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099 [TBL] [Abstract][Full Text] [Related]
2. Overview on non-melanoma skin cancers in solid organ transplant recipients. Forchetti G; Suppa M; Del Marmol V G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224 [TBL] [Abstract][Full Text] [Related]
3. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients. Funk-Debleds P; Ducroux E; Guillaud O; Ursic-Bedoya J; Decullier E; Vallin M; Euvrard S; Pageaux GP; Boillot O; Dumortier J J Am Acad Dermatol; 2018 Jul; 79(1):84-91. PubMed ID: 29307647 [TBL] [Abstract][Full Text] [Related]
4. Immunity against Non-Melanoma Skin Cancer and the Effect of Immunosuppressive Medication on Non-Melanoma Skin Cancer Risk in Solid Organ Transplant Recipients. Bakker D; Bakker WJ; Bekkenk MW; Luiten RM Cells; 2023 Oct; 12(20):. PubMed ID: 37887285 [TBL] [Abstract][Full Text] [Related]
5. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Endrizzi B; Ahmed RL; Ray T; Dudek A; Lee P Dermatol Surg; 2013 Apr; 39(4):634-45. PubMed ID: 23379978 [TBL] [Abstract][Full Text] [Related]
6. Nonmelanoma Skin Cancers After Kidney Transplant: Our 15 Years of Experience With Mammalian Target of Rapamycin Inhibitors. Okut G; Alp A; Tatar E; Simsek C; Tugmen C; Uslu A Exp Clin Transplant; 2017 Feb; 15(Suppl 1):236-239. PubMed ID: 28260475 [TBL] [Abstract][Full Text] [Related]
7. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Tessari G; Girolomoni G Dermatol Surg; 2012 Oct; 38(10):1622-30. PubMed ID: 22805312 [TBL] [Abstract][Full Text] [Related]
8. Management of non-melanoma skin cancer in solid organ transplant recipients. Specchio F; Saraceno R; Chimenti S; Nistico S Int J Immunopathol Pharmacol; 2014; 27(1):21-4. PubMed ID: 24674675 [TBL] [Abstract][Full Text] [Related]
9. Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients. Cheng JY; Li FY; Ko CJ; Colegio OR JAMA Dermatol; 2018 Jan; 154(1):60-66. PubMed ID: 29167858 [TBL] [Abstract][Full Text] [Related]
10. Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients. Solomon-Cohen E; Reiss-Huss S; Hodak E; Davidovici B Dermatology; 2022; 238(1):161-166. PubMed ID: 33902035 [TBL] [Abstract][Full Text] [Related]
11. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. Kreher MA; Noland MMB; Konda S; Longo MI; Valdes-Rodriguez R J Am Acad Dermatol; 2023 Mar; 88(3):521-530. PubMed ID: 36460257 [TBL] [Abstract][Full Text] [Related]
12. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413 [No Abstract] [Full Text] [Related]
13. Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs). Asgari MM; Arron ST; Warton EM; Quesenberry CP; Weisshaar D J Am Acad Dermatol; 2015 Sep; 73(3):444-50. PubMed ID: 26138646 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review. Schauder DM; Kim J; Nijhawan RI JAMA Dermatol; 2020 Oct; 156(10):1117-1124. PubMed ID: 32639538 [TBL] [Abstract][Full Text] [Related]
15. Skin cancer in organ transplant recipients--where do we stand today? Ulrich C; Kanitakis J; Stockfleth E; Euvrard S Am J Transplant; 2008 Nov; 8(11):2192-8. PubMed ID: 18782290 [TBL] [Abstract][Full Text] [Related]
16. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients. Leblanc KG; Hughes MP; Sheehan DJ Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. Kim C; Cheng J; Colegio OR Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693 [TBL] [Abstract][Full Text] [Related]
18. Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US. Sargen MR; Cahoon EK; Yu KJ; Madeleine MM; Zeng Y; Rees JR; Lynch CF; Engels EA JAMA Dermatol; 2022 Apr; 158(4):414-425. PubMed ID: 35262623 [TBL] [Abstract][Full Text] [Related]
19. Periocular Skin Cancer in Solid Organ Transplant Recipients. Perry JD; Polito SC; Chundury RV; Singh AD; Fritz MA; Vidimos AT; Gastman BR; Koyfman SA Ophthalmology; 2016 Jan; 123(1):203-8. PubMed ID: 26520170 [TBL] [Abstract][Full Text] [Related]
20. Timing of mTORI usage and outcomes in kidney transplant recipients. Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]